MannKind: Facts And Fundamentals Over Fiction And Fear
Jun 19 2013, BY: George Rho
Poorly worded reports by another web-based purveyor of stock information, theflyonthewall, which appeared to link potentially serious problems with Eli Lilly's (LLY) antipsychotic drug Zyprexa with MannKind.
Moreover, the company has completed all of the necessary testing of its flagship product and appears well on its way to commercialization. Indeed, the fundamentals and outlook that motivated us to write two previous articles on MannKind - Pricing A Highly ProbableTakeover Of MannKind and Pricing MannKind Corporation On A Stand-Alone Basis - stay intact, Tuesday's price action notwithstanding.
June 17, 2013 Baker Bros Advisors LLC Portfolio
HALO Halozyme Therapeutics Inc 17 - $6.22 $18,346,000 3,182,251 0.48% 6,471,000 1,412,475 3.071 Biotechnology
if so were all doomed
Why MannKind Is Poised to Pull Back Motley Fool
By Brian Pacampara | More Articles | Save For Later
June 18, 2013 | C
Seeking Alpha Updated 6/10/13
Mann has plenty of money to burn and shorts need to fully consider this obvious fact. It is not likely Mannkind will run out of money because Mann can personally afford to keep the company afloat. Mann can also afford the very best scientists money can buy to ensure the company will eventually succeed in getting their drugs to market. I
Tues bear attack
just came out
long. This is very undervalued BTW.
The Street By:Adam F. 6/11
Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)
Baker Brothers, already the largest Acadia shareholder, disclosed an upsized 23 percent stake in the company last week. High-conviction stocks in the Baker Brothers portfolio -- think Seattle Genetics (SGEN_) and Pharmacyclics (PCYC_) -- tend to perform really well, sometimes regardless of near-term
Oh yeah, it's worth noting that Acadia has a potential blockbuster drug in pimavanserin,